Flu vaccine uptake (%) in adults aged 65 and over, who received the flu vaccination between 1st September to the end of February as recorded in the GP record. The February collection has been adopted for our end of season figures from 2017 to 2018. All previous data is the same definitions but until the end of January rather than February to consider data returning from outside the practice and later in practice vaccinations.RationaleInfluenza (also known as Flu) is a highly infectious viral illness spread by droplet infection. The flu vaccination is offered to people who are at greater risk of developing serious complications if they catch the flu. The seasonal influenza programme for England is set out in the Annual Flu Letter. Both the flu letter and the flu plan have the support of the Chief Medical Officer (CMO), Chief Pharmaceutical Officer (CPhO), and Director of Nursing.Vaccination coverage is the best indicator of the level of protection a population will have against vaccine-preventable communicable diseases. Immunisation is one of the most effective healthcare interventions available, and flu vaccines can prevent illness and hospital admissions among these groups of people. Increasing the uptake of the flu vaccine among these high-risk groups should also contribute to easing winter pressure on primary care services and hospital admissions. Coverage is closely related to levels of disease. Monitoring coverage identifies possible drops in immunity before levels of disease rise.The UK Health Security Agency (UKHSA) will continue to provide expert advice and monitoring of public health, including immunisation. NHS England now has responsibility for commissioning the flu programme, and GPs continue to play a key role. NHS England teams will ensure that robust plans are in place locally and that high vaccination uptake levels are reached in the clinical risk groups. For more information, see the Green Book chapter 19 on Influenza.The Annual Flu Letter sets out the national vaccine uptake ambitions each year. In 2021 to 2022, the national ambition was to achieve at least 85 percent vaccine uptake in those aged 65 and over. Prior to this, the national vaccine uptake ambition was 75 percent, in line with WHO targets.Definition of numeratorNumerator is the number of vaccinations administered during the influenza season between 1st September and the end of February.Definition of denominatorDenominator is the GP registered population on the date of extraction including patients who have been offered the vaccine but refused it, as the uptake rate is measured against the overall eligible population. For more detailed information please see the user guide, available to view and download from https://www.gov.uk/government/collections/vaccine-uptake#seasonal-flu-vaccine-uptakeCaveatsRead codes are primarily used for data collection purposes to extract vaccine uptake data for patients who fall into one or more of the designated clinical risk groups. The codes identify individuals at risk, and therefore eligible for flu vaccination. However, it is important to note that there may be some individuals with conditions not specified in the recommended risk groups for vaccination, who may be offered influenza vaccine by their GP based on clinical judgement and according to advice contained in the flu letter and Green Book, and thus are likely to fall outside the listed Read codes. Therefore, this data should not be used for GP payment purposes.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.

This data originates from the Public Health Outcomes tool currently presents data for available indicators for upper tier local authority levels, collated by Public Health England (PHE).

The data currently published here are the baselines for the Public Health Outcomes Framework, together with more recent data where these are available. The baseline period is 2010 or equivalent, unless these data are unavailable or not deemed to be of sufficient quality. The first data were published in this tool as an official statistics release in November 2012. Future official statistics updates will be published as part of a quarterly update cycle in August, November, February and May.

The definition, rationale, source information, and methodology for each indicator can be found within the spreadsheet.

Data included in the spreadsheet:

0.1i - Healthy life expectancy at birth
0.1ii - Life Expectancy at birth
0.1ii - Life Expectancy at 65
0.2i - Slope index of inequality in life expectancy at birth based on national deprivation deciles within England
0.2ii - Number of upper tier local authorities for which the local slope index of inequality in life expectancy (as defined in 0.2iii) has decreased
0.2iii - Slope index of inequality in life expectancy at birth within English local authorities, based on local deprivation deciles within each area
0.2iv - Gap in life expectancy at birth between each local authority and England as a whole
0.2v - Slope index of inequality in healthy life expectancy at birth based on national deprivation deciles within England
1.01i - Children in poverty (all dependent children under 20)
1.01ii - Children in poverty (under 16s)
1.02i - School Readiness: The percentage of children achieving a good level of development at the end of reception
1.02i - School Readiness: The percentage of children with free school meal status achieving a good level of development at the end of reception
1.02ii - School Readiness: The percentage of Year 1 pupils achieving the expected level in the phonics screening check
1.02ii - School Readiness: The percentage of Year 1 pupils with free school meal status achieving the expected level in the phonics screening check
1.03 - Pupil absence
1.04 - First time entrants to the youth justice system
1.05 - 16-18 year olds not in education employment or training
1.06i - Adults with a learning disability who live in stable and appropriate accommodation
1.06ii - % of adults in contact with secondary mental health services who live in stable and appropriate accommodation
1.07 - People in prison who have a mental illness or a significant mental illness
1.08i - Gap in the employment rate between those with a long-term health condition and the overall employment rate
1.08ii - Gap in the employment rate between those with a learning disability and the overall employment rate
1.08iii - Gap in the employment rate for those in contact with secondary mental health services and the overall employment rate
1.09i - Sickness absence - The percentage of employees who had at least one day off in the previous week
1.09ii - Sickness absence - The percent of working days lost due to sickness absence
1.10 - Killed and seriously injured (KSI) casualties on England's roads
1.11 - Domestic Abuse
1.12i - Violent crime (including sexual violence) - hospital admissions for violence
1.12ii - Violent crime (including sexual violence) - violence offences per 1,000 population
1.12iii- Violent crime (including sexual violence) - Rate of sexual offences per 1,000 population
1.13i - Re-offending levels - percentage of offenders who re-offend
1.13ii - Re-offending levels - average number of re-offences per offender
1.14i - The rate of complaints about noise
1.14ii - The percentage of the population exposed to road, rail and air transport noise of 65dB(A) or more, during the daytime
1.14iii - The percentage of the population exposed to road, rail and air transport noise of 55 dB(A) or more during the night-time
1.15i - Statutory homelessness - homelessness acceptances
1.15ii - Statutory homelessness - households in temporary accommodation
1.16 - Utilisation of outdoor space for exercise/health reasons
1.17 - Fuel Poverty
1.18i - Social Isolation: % of adult social care users who have as much social contact as they would like
1.18ii - Social Isolation: % of adult carers who have as much social contact as they would like
1.19i - Older people's perception of community safety - safe in local area during the day
1.19ii - Older people's perception of community safety - safe in local area after dark
1.19iii - Older people's perception of community safety - safe in own home at night
2.01 - Low birth weight of term babies
2.02i - Breastfeeding - Breastfeeding initiation
2.02ii - Breastfeeding - Breastfeeding prevalence at 6-8 weeks after birth
2.03 - Smoking status at time of delivery
2.04 - Under 18 conceptions
2.04 - Under 18 conceptions: conceptions in those aged under 16
2.06i - Excess weight in 4-5 and 10-11 year olds - 4-5 year olds
2.06ii - Excess weight in 4-5 and 10-11 year olds - 10-11 year olds
2.07i - Hospital admissions caused by unintentional and deliberate injuries in children (aged 0-14 years)
2.07i - Hospital admissions caused by unintentional and deliberate injuries in children (aged 0-4 years)
2.07ii - Hospital admissions caused by unintentional and deliberate injuries in young people (aged 15-24)
2.08 - Emotional well-being of looked after children
2.12 - Excess Weight in Adults
2.13i - Percentage of physically active and inactive adults - active adults
2.13ii - Percentage of active and inactive adults - inactive adults
2.14 - Smoking Prevalence
2.14 - Smoking prevalence - routine & manual
2.15i - Successful completion of drug treatment - opiate users
2.15ii - Successful completion of drug treatment - non-opiate users
2.17 - Recorded diabetes
2.18 - Alcohol related admissions to hospital
2.19 - Cancer diagnosed at early stage (Experimental Statistics)
2.20i - Cancer screening coverage - breast cancer
2.20ii - Cancer screening coverage - cervical cancer
2.21vii - Access to non-cancer screening programmes - diabetic retinopathy
2.22iii - Cumulative % of the eligible population aged 40-74 offered an NHS Health Check
2.22iv - Cumulative % of the eligible population aged 40-74 offered an NHS Health Check who received an NHS Health Check
2.22v - Cumulative % of the eligible population aged 40-74 who received an NHS Health check
2.23i - Self-reported well-being - people with a low satisfaction score
2.23ii - Self-reported well-being - people with a low worthwhile score
2.23iii - Self-reported well-being - people with a low happiness score
2.23iv - Self-reported well-being - people with a high anxiety score
2.24i - Injuries due to falls in people aged 65 and over (Persons)
2.24i - Injuries due to falls in people aged 65 and over (males/females)
2.24ii - Injuries due to falls in people aged 65 and over - aged 65-79
2.24iii - Injuries due to falls in people aged 65 and over - aged 80+
3.01 - Fraction of mortality attributable to particulate air pollution
3.02i - Chlamydia screening detection rate (15-24 year olds) - Old NCSP data
3.02ii - Chlamydia screening detection rate (15-24 year olds) - CTAD
3.03i - Population vaccination coverage - Hepatitis B (1 year old)
3.03i - Population vaccination coverage - Hepatitis B (2 years old)
3.03iii - Population vaccination coverage - Dtap / IPV / Hib (1 year old)
3.03iii - Population vaccination coverage - Dtap / IPV / Hib (2 years old)
3.03iv - Population vaccination coverage - MenC
3.03v - Population vaccination coverage - PCV
3.03vi - Population vaccination coverage - Hib / MenC booster (2 years old)
3.03vi - Population vaccination coverage - Hib / Men C booster (5 years)
3.03vii - Population vaccination coverage - PCV booster
3.03viii - Population vaccination coverage - MMR for one dose (2 years old)
3.03ix - Population vaccination coverage - MMR for one dose (5 years old)
3.03x - Population vaccination coverage - MMR for two doses (5 years old)
3.03xii - Population vaccination coverage - HPV
3.03xiii - Population vaccination coverage - PPV
3.03xiv - Population vaccination coverage - Flu (aged 65+)
3.03xv - Population vaccination coverage - Flu (at risk individuals)
3.04 - People presenting with HIV at a late stage of infection
3.05i - Treatment completion for TB
3.05ii - Incidence of TB
3.06 - NHS organisations with a board approved sustainable development management plan
4.01 - Infant mortality
4.02 - Tooth decay in children aged 5
4.03 - Mortality rate from causes considered preventable
4.04i - Under 75 mortality rate from all cardiovascular diseases
4.04ii - Under 75 mortality rate from cardiovascular diseases considered preventable
4.05i - Under 75 mortality rate from cancer
4.05ii - Under 75 mortality rate from cancer considered preventable
4.06i - Under 75 mortality rate from liver disease
4.06ii - Under 75 mortality rate from liver disease considered preventable
4.07i - Under 75 mortality rate from respiratory disease
4.07ii - Under 75 mortality rate from respiratory disease considered preventable
4.08 - Mortality from communicable diseases
4.09 - Excess under 75 mortality rate in adults with serious mental illness
4.10 - Suicide rate
4.11 - Emergency readmissions within 30 days of discharge from hospital
4.12i - Preventable sight loss - age related macular degeneration (AMD)
4.12ii - Preventable sight loss - glaucoma
4.12iii - Preventable sight loss - diabetic eye disease
4.12iv - Preventable sight loss - sight loss certifications
4.14i - Hip fractures in

Indicators from the Opinions and Lifestyle Survey (OPN) related to coronavirus (COVID-19) boosters, flu vaccines and lateral flow tests for people in Great Britain.

IntroductionThe key to understanding the COVID-19 correlates of protection is assessing vaccine-induced immunity in different demographic groups. Young people are at a lower risk of COVID-19 mortality, females are at a lower risk than males, and females often generate stronger immune responses to vaccination.MethodsWe studied immune responses to two doses of BNT162b2 Pfizer COVID-19 vaccine in an adolescent cohort (n = 34, ages 12–16), an age group previously shown to elicit significantly greater immune responses to the same vaccine than young adults. Adolescents were studied with the aim of comparing their response to BNT162b2 to that of adults; and to assess the impacts of other factors such as sex, ongoing SARS–CoV–2 infection in schools, and prior exposure to endemic coronaviruses that circulate at high levels in young people. At the same time, we were able to evaluate immune responses to the co-administered live attenuated influenza vaccine. Blood samples from 34 adolescents taken before and after vaccination with COVID-19 and influenza vaccines were assayed for SARS–CoV–2-specific IgG and neutralising antibodies and cellular immunity specific for SARS–CoV–2 and endemic betacoronaviruses. The IgG targeting influenza lineages contained in the influenza vaccine were also assessed.ResultsRobust neutralising responses were identified in previously infected adolescents after one dose, and two doses were required in infection-naïve adolescents. As previously demonstrated, total IgG responses to SARS–CoV-2 Spike were significantly higher among vaccinated adolescents than among adults (aged 32–52) who received the BNT162b2 vaccine (comparing infection-naïve, 49,696 vs. 33,339; p = 0.03; comparing SARS-CoV–2 previously infected, 743,691 vs. 269,985; p

Description of how seasonal influenza vaccine is offered to individuals in risk groups that are part of the vaccine recommendations, in 2019/2020, by country.